Condition: Primary Immune Thrombocytopenia (ITP) · Sponsor: Jiangsu BioJeTay Biotechnology Co., Ltd.
A randomized, double-blind, placebo-controlled design was designed to evaluate the safety and tolerability, pharmacokinetic/pharmacodynamic profile, and immunogenicity of multiple administration of STSA-1301 subcutaneous injection in healthy subjects and patients with ITP, and to further explore the initial efficacy of STSA-1301 subcutaneous injection in patients with ITP
This description comes directly from the study's public registry record.
Yanli Wang · +86 13311367132 · wangyanli@staidson.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Bengbu Medical College | Bengbu, Anhui, China | Recruiting |
| Peking University People's Hospital | Beijing, Beijing Municipality, China | Recruiting |
| North China University of Science and Technology Affiliated Hospital | Tangshan, Hebei, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
| The First Affiliated Hospital of Nanchang University | Nanchang, Jiangxi, China | Recruiting |
| Xi'an Central Hospital | Xi’an, Shanxi, China | Recruiting |
| Hospital of Hematology, Chinese Academy of Medical Sciences | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06929299